B Bouvard1, J Chatelais2, P Soulié3, E Hoppé2, P Saulnier4, O Capitain3, M Mege5, N Mesgouez-Nebout5, E Jadaud5, S Abadie-Lacourtoisie3, M Campone3, E Legrand6. 1. Department of Rheumatology, University Hospital, Angers, France; Research Group on Bone Remodeling and BioMaterials UPRES EA 4658, University Hospital, Angers, France. Electronic address: bebouvard@chu-angers.fr. 2. Department of Rheumatology, University Hospital, Angers, France. 3. Division of Oncology, Integrated Centre of Oncology, Angers, France. 4. Biostatistics and Methodology Unit, University Hospital, Angers, France. 5. Division of Radiotherapy, Integrated Centre of Oncology, Angers, France. 6. Department of Rheumatology, University Hospital, Angers, France; Research Group on Bone Remodeling and BioMaterials UPRES EA 4658, University Hospital, Angers, France.
Abstract
BACKGROUND: Risk factors for breast cancer relapse are well-known, such as large tumour size or lymph node involvement. The aim of our study was to analyse the influence of bone mineral density, fractures and bisphosphonate or vitamin D prescription on 10 years' breast cancer outcome. PATIENTS AND METHODS: This is a longitudinal and prospective cohort of 450 postmenopausal women with local oestrogen receptor (ER)+ breast cancer. For every patient, we analysed tumour characteristics, bone status at the beginning of aromatase inhibitor treatment and 10 years' cancer outcome with Cox model. RESULTS: Mean follow-up was 10.3 ± 3.0 years. Seventy nine women died, and 75 had a relapse; 30.7% had a history of fracture, 16.9% had a T-score ≤ -2.5 and 11.3% had vitamin D deficiency. Bisphosphonates were prescribed to 35.3% women for osteoporosis for a mean duration of 5 ± 1.7 years. Tumour size (hazard ratio [HR] = 1.32, P ≤ 0.01) and the number of lymph nodes involved (HR = 1.07, P = 0.03) were significantly associated with relapse. Bisphosphonate treatment was significantly associated with a decreased risk of relapse (HR = 0.51, P = 0.03). Age at cancer diagnosis (HR = 1.07, P ≤ 0.01) and vitamin D deficiency (HR = 1.85, P = 0.04) were significantly associated with an increased risk of death, whereas bisphosphonate treatment was associated with a decreased risk of death (HR = 0.46, P = 0.01). CONCLUSION: Osteoporosis treatment, including vitamin D and bisphosphonates, is associated with a 50% reduction of relapse and death in women treated with aromatase inhibitors for ER+ breast cancer.
BACKGROUND: Risk factors for breast cancer relapse are well-known, such as large tumour size or lymph node involvement. The aim of our study was to analyse the influence of bone mineral density, fractures and bisphosphonate or vitamin D prescription on 10 years' breast cancer outcome. PATIENTS AND METHODS: This is a longitudinal and prospective cohort of 450 postmenopausal women with local oestrogen receptor (ER)+ breast cancer. For every patient, we analysed tumour characteristics, bone status at the beginning of aromatase inhibitor treatment and 10 years' cancer outcome with Cox model. RESULTS: Mean follow-up was 10.3 ± 3.0 years. Seventy nine women died, and 75 had a relapse; 30.7% had a history of fracture, 16.9% had a T-score ≤ -2.5 and 11.3% had vitamin D deficiency. Bisphosphonates were prescribed to 35.3% women for osteoporosis for a mean duration of 5 ± 1.7 years. Tumour size (hazard ratio [HR] = 1.32, P ≤ 0.01) and the number of lymph nodes involved (HR = 1.07, P = 0.03) were significantly associated with relapse. Bisphosphonate treatment was significantly associated with a decreased risk of relapse (HR = 0.51, P = 0.03). Age at cancer diagnosis (HR = 1.07, P ≤ 0.01) and vitamin D deficiency (HR = 1.85, P = 0.04) were significantly associated with an increased risk of death, whereas bisphosphonate treatment was associated with a decreased risk of death (HR = 0.46, P = 0.01). CONCLUSION:Osteoporosis treatment, including vitamin D and bisphosphonates, is associated with a 50% reduction of relapse and death in women treated with aromatase inhibitors for ER+ breast cancer.
Authors: Anna Jansana; Laia Domingo; Berta Ibañez; Alexandra Prados; Isabel Del Cura; Maria Padilla-Ruiz; Teresa Sanz; Beatriz Poblador; Ibai Tamayo; Antonio Gimeno; Angel Alberquilla; Mercè Abizanda; Mercè Comas; Manuela Lanzuela; Rossana Burgui; Antonio Diaz Holgado; Talita Duarte-Salles; Conchi Moreno; Javier Louro; Javier Baquedano; Cristobal Molina; Maria Del Carmen Martinez; Javier Gorricho; Maximino Redondo; Xavier Castells; Maria Sala Journal: J Cancer Surviv Date: 2021-03-23 Impact factor: 4.442
Authors: Irene E G van Hellemond; Carolien H Smorenburg; Petronella G M Peer; Astrid C P Swinkels; Caroline M Seynaeve; Maurice J C van der Sangen; Judith R Kroep; Hiltje de Graaf; Aafke H Honkoop; Frans L G Erdkamp; Franchette W P J van den Berkmortel; Wilfred K de Roos; Sabine C Linn; Alexander L T Imholz; Maaike de Boer; Vivianne C G Tjan-Heijnen Journal: Breast Cancer Res Treat Date: 2020-03-02 Impact factor: 4.872
Authors: Komal Waqas; Joana Lima Ferreira; Elena Tsourdi; Jean-Jacques Body; Peyman Hadji; M C Zillikens Journal: J Bone Oncol Date: 2021-03-18 Impact factor: 4.072